Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and understand the proteome in the United States. The company is developing the Nautilus Voyager Platform, an end-to-end solution that includes instruments, reagents, consumables, and software analysis. Its offerings include the Nautilus Voyager Instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling. This system deposits protein libraries onto a flow cell and rapidly processes labeled multi-affinity reagent binding and imaging cycles to decode and quantify proteins in biological samples. Nautilus Biotechnology also provides single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers for multi-cycle analysis runs. The company has research collaboration agreements with Genentech, Buck Institute, Allen Institute, Cornell University, the Qatar Foundation, and the Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.